Dianabol For Sale: Effectivity And Regulation
Dianabol (Methandrostenolone)
- Class & Structure: Synthetic anabolic‑androgenic steroid (AAS) derived from testosterone; contains a 17α‑methyl group and an additional 4‑methyl group, giving it a "double‑bumped" shape.
- Administration: Oral tablets (commonly 2–6 mg once or twice daily). The oral route requires hepatic metabolism, so it is hepatotoxic at higher doses.
- Half‑life & Action: ~12 h; peaks in the bloodstream within a few hours after ingestion.
- Effects: Strong anabolic activity with moderate androgenic potency. Rapid muscle mass gain, increased strength, and www.bidbarg.com early improvements in performance (especially when combined with other compounds).
- Side‑effects: Liver strain or damage (especially at doses >6 mg/day), mild water retention, possible acne, mood swings. Rarely causes virilization in women.
2. What is "the difference" between S4 and S4‑P?
| Feature | S4 | S4‑P |
|---|---|---|
| Structure | Standard 17α‑acetylated, 3‑hydroxyl steroid (like many anabolic steroids). | Contains a progestin‑type group at the C3 position: an "oxo‑" or "enone" system that makes it more progestogenic. |
| Progestogenic activity | Minimal – primarily acts through androgen receptors. | High – behaves much like a synthetic progesterone (e.g., medroxyprogesterone). |
| Metabolism | Rapidly cleared, mainly via 3‑oxidation and conjugation. | More resistant to metabolism; longer half‑life due to steric hindrance at C3. |
| Side‑effects | Can cause gynecomastia if testosterone levels rise (via aromatase). | Additional side‑effects: mood swings, water retention, nausea, increased appetite, weight gain. |
| Typical dosage | 0.5–1 mg daily for acne or hair loss; may be combined with minoxidil. | 0.25–0.75 mg daily (often in divided doses) to reduce side‑effects; usually taken at night. |
---
How the Body Processes the Two Forms
| Step | Normal Testosterone | C3‑Modified Testosterone |
|---|---|---|
| Synthesis | Endogenous production in Leydig cells of testes or adrenal cortex (in men). | Exogenously supplied; does not require conversion. |
| Transport | 99 % bound to SHBG and albumin → very low free fraction. | Same binding profile; the same proportion is "free" but due to the chemical change the free hormone may be less able to cross cell membranes. |
| Cellular Uptake | Diffuses through lipid bilayer into cells where it binds androgen receptors (AR). | Diffusion significantly reduced; the molecule’s altered polarity and steric hindrance limit passive entry, especially in tissues with low lipid content. |
| Metabolism | Rapid 5α‑reduction by 5α‑reductase → DHT → potent AR activation; further conjugation & excretion. | The bulky group may inhibit 5α‑reductase recognition; less conversion to DHT. Conjugation may also be altered, potentially increasing renal clearance or hepatic uptake. |
| Target Tissue Effect | High concentration in prostate, skin, hair follicles → pronounced androgenic effects (growth, hyperplasia). | Lower penetration leads to reduced stimulation of androgen‑dependent tissues; systemic side‑effects like gynecomastia or acne may diminish due to lower bioavailability at target sites. |
---
5. Predicted Pharmacological Profile
| Property | Likely Value |
|---|---|
| Molecular weight | ~450 Da (within drug‑like range) |
| LogP | ~3–4 (balanced lipophilicity) |
| Topological polar surface area (tPSA) | 70–90 Ų (moderate, allows membrane crossing) |
| Oral bioavailability | Moderate; may require formulation to improve absorption |
| Half‑life | ~12–24 h (due to moderate lipophilicity and metabolic stability) |
| Metabolic pathway | Phase I oxidation of the side chain; phase II conjugation of the phenolic OH |
| Toxicity profile | Lower acute toxicity compared to 3,4‑DMP; hepatotoxicity risk remains but reduced |
---
Conclusion
The designed compound, 2‑(1‑(pyridin‑3‑yl)ethyl)oxyphenol, strategically incorporates a pyridine ring for improved solubility and a phenolic hydroxyl group to reduce metabolic liability. These structural changes are expected to:
Lower acute toxicity relative to 3,4‑DMP.
Maintain or improve the ability to permeate biological membranes (due to the aromatic system).
- Retain an acceptable degree of lipophilicity for cell penetration while enhancing aqueous solubility.
